News and Announcements
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) receives $2.2 million R&D cash rebate
- Published February 11, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Australian oncology-focused biotechnology company, Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) has received a $2.2 million R&D cash rebate.
The ASX listed company is pleased to confirm they received $2,191,257.95 from the Australian Taxation Office under the R&D tax Incentive Program for the financial year ending 30 June 2018.
Kazia CEO, Dr James Garner, said: ““The R&D tax rebate is an important, non-dilutive source of funding for the Company.”
“The amount is consistent with the expectations laid out in our financial reports, and the funds will be invested in progressing our two clinical programs.”
“This is an important year for Kazia, with multiple data read-outs anticipated in the near future.”
About Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA)
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
